Justin Petrone

The genomics and diagnostics communities are keen to see clear implementation objectives set as the EHDS is rolled out over the next decade.

Discussions are underway within the French government regarding strategies to increase cancer-related sequencing and diagnostic yield, among other issues.

Can.Heal has produced a dozen reports that will inform both EU policies and national health strategies for personalized cancer treatment and prevention going forward.

Should the results be favorable, it could lay the foundation for whole-genome sequencing to be the standard of care for newborn screening in Greece.

Mursla Bio, a Cambridge, UK-based company that focuses on EV isolation, biomarker discovery from EV cargo, and EV assays for clinical use, is an EVEREST participant.

The firm last week announced it received funding that will allow it to complete development of the test, called Myelo-Scan, by the end of 2026.

The Swedish single-cell RNA-sequencing startup plans to bring new applications to its services menu as a partnership with MGI begins to yield kitted products.

While the researchers have no plans to sell RNA chips based on the technology, they do intend to commercialize a device for synthesizing high-density arrays.

GMS will also use the funding for studies related to childhood cancer and rare diseases and to continue the development of a National Genomics Platform.

The biobank will use the genome sequencing data to inform various personalized medicine projects focused on cardiovascular disease, pharmacogenomics, cancer, and rare diseases.